Progress in defining multidrug resistance in leukemia

János Kappelmayer, Ágnes Simon, Flóra Kiss, Zsuzsa Hevessy

Research output: Contribution to journalReview article

4 Citations (Scopus)


Multidrug resistance (MDR) is a naturally occurring defense phenomenon by which cells battle against chemically foreign substances (xenobiotics), including some cytotoxic drugs. Membrane transporter hyperactivity is a major contributor to MDR and is the primary target of both diagnostic and therapeutic interventions. Multi-xenobiotic resistance can be exploited as several fluorescent indicator probes are extruded by the same drug transporters, making it possible to quantitatively measure MDR activity in cell lines and clinical samples by flow cytometry. The literature on MDR is reported in a number of different formats, making it difficult to compare data from various groups. This article will briefly review the pothomechanism, then focus upon the diagnostic approach, the interpretation of results from clinical samples and correlations with other variables. The authors believe that a standardized MDR assay, as well as a suitable monitoring test, may become a prognostic marker in several types of leukemia.

Original languageEnglish
Pages (from-to)209-217
Number of pages9
JournalExpert Review of Molecular Diagnostics
Issue number2
Publication statusPublished - Mar 1 2004


  • Calcein
  • Drug resistance
  • Flow cytometry
  • P-glycoprotein
  • Verapimil

ASJC Scopus subject areas

  • Pathology and Forensic Medicine
  • Molecular Medicine
  • Molecular Biology
  • Genetics

Fingerprint Dive into the research topics of 'Progress in defining multidrug resistance in leukemia'. Together they form a unique fingerprint.

  • Cite this